Literature DB >> 6681588

A new life-long hemorrhagic disorder due to excess plasminogen activator.

N A Booth, B Bennett, G Wijngaards, J H Grieve.   

Abstract

A life-long bleeding disorder is described, characterized by hemorrhage occurring after surgery, injury, or dental extraction, and finally by spontaneous intracerebral bleeding. No abnormality of platelet function or plasma coagulation was demonstrable, but grossly enhanced overall fibrinolytic activity was present. The patient had, additionally, a hyperlipidemia with gross arterial atheroma and a family history of myocardial infarction but not of any hemorrhagic disorder. Laboratory studies led to the conclusion that the enhanced fibrinolysis was due to consistently greatly raised levels of a plasma plasminogen activator physically and immunologically related to that in human tissues and blood vessel endothelium. No deficiency of any known inhibitor of fibrinolysis was detected. Free plasmin was not detectable in functional assays but continuous intravascular plasmin generation clearly occurred as evidenced by presence of plasmin-alpha 2-antiplasmin complexes and of fibrin/fibrinogen-related antigens. Excessive production of plasminogen activator appeared to have occurred throughout life and to be independent of the hyperlipidemia. The pathologically increased fibrinolytic activity may have accounted for the complete absence of detectable thrombotic vascular occlusion at autopsy despite extensive arterial disease with severe narrowing of coronary and cerebral arteries.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6681588

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  10 in total

1.  Plasminogen activators in alcoholic cirrhosis: demonstration of increased tissue type and urokinase type activator.

Authors:  N A Booth; J A Anderson; B Bennett
Journal:  J Clin Pathol       Date:  1984-07       Impact factor: 3.411

Review 2.  Plasminogen activator inhibitor type-1 (part one): basic mechanisms, regulation, and role for thromboembolic disease.

Authors:  K Huber
Journal:  J Thromb Thrombolysis       Date:  2001-05       Impact factor: 2.300

Review 3.  Tissue-type plasminogen activator. A review of its pharmacology and therapeutic use as a thrombolytic agent.

Authors:  D Collen; H R Lijnen; P A Todd; K L Goa
Journal:  Drugs       Date:  1989-09       Impact factor: 9.546

4.  Disturbed fibrinolysis in patients with inflammatory bowel disease. A study in blood plasma, colon mucosa, and faeces.

Authors:  E de Jong; R J Porte; E A Knot; J H Verheijen; J Dees
Journal:  Gut       Date:  1989-02       Impact factor: 23.059

5.  Bleeding diathesis due to decreased functional activity of type 1 plasminogen activator inhibitor.

Authors:  R R Schleef; D L Higgins; E Pillemer; L J Levitt
Journal:  J Clin Invest       Date:  1989-05       Impact factor: 14.808

Review 6.  Clinical disorders of fibrinolysis: a critical review.

Authors:  R B Francis
Journal:  Blut       Date:  1989-07

7.  Model thrombi formed under flow reveal the role of factor XIII-mediated cross-linking in resistance to fibrinolysis.

Authors:  N J Mutch; J S Koikkalainen; S R Fraser; K M Duthie; M Griffin; J Mitchell; H G Watson; N A Booth
Journal:  J Thromb Haemost       Date:  2010-09       Impact factor: 5.824

8.  In vitro inhibition of human malignant brain tumour cell line proliferation by anti-urokinase-type plasminogen activator monoclonal antibodies.

Authors:  M S Abaza; F A Shaban; R K Narayan; M Z Atassi
Journal:  Br J Cancer       Date:  1998-12       Impact factor: 7.640

9.  Whole exome sequencing of a single osteosarcoma case--integrative analysis with whole transcriptome RNA-seq data.

Authors:  Ene Reimann; Sulev Kõks; Xuan Dung Ho; Katre Maasalu; Aare Märtson
Journal:  Hum Genomics       Date:  2014-12-11       Impact factor: 4.639

10.  Decreased fibrinolytic activity in porcine-to-primate cardiac xenotransplantation.

Authors:  M F Kalady; J H Lawson; R D Sorrell; J L Platt
Journal:  Mol Med       Date:  1998-09       Impact factor: 6.354

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.